Mice Transgenic for CD4-Specific Human CD4, CCR5 and Cyclin T1 Expression: A New Model for Investigating HIV-1 Transmission and Treatment Efficacy

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Seay, Kieran ^a   Qi, Xiaohua ^a   Zheng, Jian Hua ^a   Zhang, Cong ^a   Chen, Ken ^a   Dutta, Monica ^a   Deneroff, Kathryn ^a   Ochsenbauer, Christina ^b   Kappes, John C ^b,c   Littman, Dan R ^d   Goldstein, Harris ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b and Clinical Center   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CYCLIN T1; INDINAVIR; LAMIVUDINE; LENTIVIRUS VECTOR; LUCIFERASE; NEUTRALIZING ANTIBODY; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VRC 01; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BIOLUMINESCENCE; CCR5 GENE; CD4 GENE; CELLULAR DISTRIBUTION; CLADISTICS; CONTROLLED STUDY; CYCLIN T1 GENE; DRUG BLOOD LEVEL; ENHANCER REGION; FOUNDER EFFECT; GENE; GENETIC TRANSDUCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INOCULATION; LEUKOCYTE; LONG TERMINAL REPEAT; LUNG PARENCHYMA; LYMPH NODE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RENILLA; SENSITIVITY AND SPECIFICITY; SMALL INTESTINE; SPLEEN; TRANSGENE; TRANSGENIC MOUSE; TREATMENT RESPONSE; UTERINE CERVIX MUCOSA; VAGINA MUCOSA; VIRUS ENTRY; VIRUS INHIBITION; VIRUS TRANSMISSION;

ANIMALS; ANTIGENS, CD4; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CYCLIN T; DNA PRIMERS; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; RECEPTORS, CCR5;

EID: 84877779790     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063537     Document Type: Article

References (48)

1. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, et al. (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381: 661-666.
2. Imai K, Asamitsu K, Victoriano AF, Cueno ME, Fujinaga K, et al. (2009) Cyclin T1 stabilizes expression levels of HIV-1 Tat in cells. The FEBS journal 276: 7124-7133.
3. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA, (1998) A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92: 451-462.
4. Wimmer J, Fujinaga K, Taube R, Cujec TP, Zhu Y, et al. (1999) Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b. Virology 255: 182-189.
5. Mosier DE, (1996) Viral pathogenesis in hu-PBL-SCID mice. Seminars in immunology 8: 255-262.
6. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, et al. (1988) The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241: 1632-1639.
7. Baenziger S, Tussiwand R, Schlaepfer E, Mazzucchelli L, Heikenwalder M, et al. (2006) Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice. Proceedings of the National Academy of Sciences of the United States of America 103: 15951-15956.
8. Ince WL, Zhang L, Jiang Q, Arrildt K, Su L, et al. (2010) Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model. Journal of virology 84: 2740-2752.
9. Watanabe S, Ohta S, Yajima M, Terashima K, Ito M, et al. (2007) Humanized NOD/SCID/IL2Rgamma(null) mice transplanted with hematopoietic stem cells under nonmyeloablative conditions show prolonged life spans and allow detailed analysis of human immunodeficiency virus type 1 pathogenesis. J Virol 81: 13259-13264.
10. Wege AK, Melkus MW, Denton PW, Estes JD, Garcia JV, (2008) Functional and phenotypic characterization of the humanized BLT mouse model. Curr Top Microbiol Immunol 324: 149-165.
11. Zhang JX, Diehl GE, Littman DR, (2008) Relief of preintegration inhibition and characterization of additional blocks for HIV replication in primary mouse T cells. PloS one 3: e2035.
12. Edmonds TG, Ding H, Yuan X, Wei Q, Smith KS, et al. (2010) Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408: 1-13.
13. Joseph A, Zheng JH, Follenzi A, Dilorenzo T, Sango K, et al. (2008) Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity. Journal of virology 82: 3078-3089.
14. Maddon PJ, Littman DR, Godfrey M, Maddon DE, Chess L, et al. (1985) The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: a new member of the immunoglobulin gene family. Cell 42: 93-104.
15. Morgenstern JP, Land H, (1990) Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 18: 3587-3596.
16. Sun J, Soos T, Kewalramani VN, Osiecki K, Zheng JH, et al. (2006) CD4-specific transgenic expression of human cyclin T1 markedly increases human immunodeficiency virus type 1 (HIV-1) production by CD4+ T lymphocytes and myeloid cells in mice transgenic for a provirus encoding a monocyte-tropic HIV-1 isolate. Journal of virology 80: 1850-1862.
17. Ochiel DO, Ochsenbauer C, Kappes JC, Ghosh M, Fahey JV, et al. (2010) Uterine epithelial cell regulation of DC-SIGN expression inhibits transmitted/founder HIV-1 trans infection by immature dendritic cells. PLoS One 5: e14306.
18. Gelderblom HC, Vatakis DN, Burke SA, Lawrie SD, Bristol GC, et al. (2008) Viral complementation allows HIV-1 replication without integration. Retrovirology 5: 60.
19. Kutsch O, Benveniste EN, Shaw GM, Levy DN, (2002) Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol 76: 8776-8786.
20. Levy DN, Aldrovandi GM, Kutsch O, Shaw GM, (2004) Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A 101: 4204-4209.
21. Ochsenbauer C, Kappes JC, (2009) New virologic reagents for neutralizing antibody assays. Curr Opin HIV AIDS 4: 418-425.
22. Collins KR, Quinones-Mateu ME, Wu M, Luzze H, Johnson JL, et al. (2002) Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity. J Virol 76: 1697-1706.
23. Sun ZF, Denton PW, Estes JD, Othieno FA, Wei BL, et al. (2007) Intrarectal transmission, systemic infection, and CD4(+) T cell depletion in humanized mice infected with HIV-1. Journal of Experimental Medicine 204: 705-714.
24. Fidel PL Jr, Wolf NA, KuKuruga MA, (1996) T lymphocytes in the murine vaginal mucosa are phenotypically distinct from those in the periphery. Infect Immun 64: 3793-3799.
25. Iijima N, Mattei LM, Iwasaki A, (2011) Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue. Proc Natl Acad Sci U S A 108: 284-289.
26. Sango K, Joseph A, Patel M, Osiecki K, Dutta M, et al. (2010) Highly active antiretroviral therapy potently suppresses HIV infection in humanized Rag2-/-gammac-/- mice. AIDS research and human retroviruses 26: 735-746.
27. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, et al. (2003) New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 41: 4531-4536.
28. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
29. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811-817.
30. Joseph A, Zheng JH, Chen K, Dutta M, Chen C, et al. (2010) Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J Virol 84: 6645-6653.
31. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, et al. (2004) Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22: 589-594.
32. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L, (2000) Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25: 217-222.
33. Follenzi A, Naldini L, (2002) Generation of HIV-1 derived lentiviral vectors. Methods Enzymol 346: 454-465.
34. Marozsan AJ, Arts EJ, (2003) Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates. J Virol Methods 111: 111-120.
35. Doronina VA, Wu C, de Felipe P, Sachs MS, Ryan MD, et al. (2008) Site-specific release of nascent chains from ribosomes at a sense codon. Mol Cell Biol 28: 4227-4239.
36. Michel N, Goffinet C, Ganter K, Allespach I, Kewalramani VN, et al. (2009) Human cyclin T1 expression ameliorates a T-cell-specific transcriptional limitation for HIV in transgenic rats, but is not sufficient for a spreading infection of prototypic R5 HIV-1 strains ex vivo. Retrovirology 6: 2.
37. Browning J, Horner JW, Pettoello-Mantovani M, Raker C, Yurasov S, et al. (1997) Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proceedings of the National Academy of Sciences of the United States of America 94: 14637-14641.
38. Miyawaki A, (2007) Bringing bioluminescence into the picture. Nat Methods 4: 616-617.
39. Welsch S, Keppler OT, Habermann A, Allespach I, Krijnse-Locker J, et al. (2007) HIV-1 buds predominantly at the plasma membrane of primary human macrophages. PLoS Pathog 3: e36.
40. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, et al. (2010) HIV and risk environment for injecting drug users: the past, present, and future. Lancet 376: 268-284.
41. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, et al. (2012) HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492: 118-122.
42. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, et al. (2012) Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481: 81-84.
43. Pietzsch J, Gruell H, Bournazos S, Donovan BM, Klein F, et al. (2012) A mouse model for HIV-1 entry. Proc Natl Acad Sci U S A 109: 15859-15864.
44. Stevenson M, (2003) HIV-1 pathogenesis. Nature medicine 9: 853-860.
45. Mariani R, Rutter G, Harris ME, Hope TJ, Krausslich HG, et al. (2000) A block to human immunodeficiency virus type 1 assembly in murine cells. Journal of virology 74: 3859-3870.
46. Pelchen-Matthews A, Kramer B, Marsh M, (2003) Infectious HIV-1 assembles in late endosomes in primary macrophages. The Journal of cell biology 162: 443-455.
47. Sherer NM, Lehmann MJ, Jimenez-Soto LF, Ingmundson A, Horner SM, et al. (2003) Visualization of retroviral replication in living cells reveals budding into multivesicular bodies. Traffic 4: 785-801.
48. Rambaut A, Posada D, Crandall KA, Holmes EC, (2004) The causes and consequences of HIV evolution. Nat Rev Genet 5: 52-61.